Invention Grant
- Patent Title: Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
-
Application No.: US16939466Application Date: 2020-07-27
-
Publication No.: US11692169B2Publication Date: 2023-07-04
- Inventor: Philippe Duchateau , Laurent Poirot
- Applicant: Cellectis
- Applicant Address: FR Paris
- Assignee: CELLECTIS
- Current Assignee: CELLECTIS
- Current Assignee Address: FR Paris
- Agency: Arrigo, Lee, Guttman & Mouta-Bellum LLP
- Priority: DK 201470076 2014.02.14
- Main IPC: C12N5/0783
- IPC: C12N5/0783 ; A61K35/17 ; A61P35/02 ; A61P35/00
Abstract:
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Information query
